Cargando…

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study

OBJECTIVES: The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated. The aim of the present study was to clarify the clinical benefit of post-nivolumab treatment in such patients. MATERIALS AND METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Yukihiro, Kurebe, Hiroyuki, Edahiro, Ryuya, Hosono, Yuki, Nakatsubo, Saeko, Nishida, Kohei, Sawa, Nobuyuki, Ishijima, Mikako, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yamaguchi, Toshihiko, Mori, Masahide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112658/ https://www.ncbi.nlm.nih.gov/pubmed/30153300 http://dx.doi.org/10.1371/journal.pone.0203070

Ejemplares similares

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Radiation Pneumonitis with Eosinophilic Alveolitis in a Lung Cancer Patient
por: Hosono, Yuki, et al.
Publicado: (2017)

Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study
por: Yamamoto, Yuji, et al.
Publicado: (2020)

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report
por: Kuge, Tomoki, et al.
Publicado: (2021)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Three Cases of Idiopathic Diffuse Pulmonary Ossification
por: Edahiro, Ryuya, et al.
Publicado: (2018)

Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
por: Akazawa, Yuki, et al.
Publicado: (2022)

Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018)

Bronchial ethanol injection therapy for airway obstruction in lung cancer patients
por: Okabe, Fukuko, et al.
Publicado: (2021)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty
por: Miki, Keisuke, et al.
Publicado: (2018)

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis
por: Osa, Akio, et al.
Publicado: (2019)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Nivolumab‐induced sialadenitis
por: Takahashi, Saeko, et al.
Publicado: (2018)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Successful continuous nivolumab therapy for metastatic non‐small cell lung cancer after local treatment of oligometastatic lesions
por: Tobita, Satoshi, et al.
Publicado: (2020)

Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients
por: Iwahori, Kota, et al.
Publicado: (2022)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Subareolar Breast Abscess in a Male: A Case Report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Radiation-Associated Breast Angiosarcoma
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Near‐infrared photoimmunotherapy (NIR‐PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes
por: Hirata, Hajime, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
por: Kaneda, Toshihiko, et al.
Publicado: (2018)

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
por: Akamatsu, Hiroaki, et al.
Publicado: (2022)

Successful treatment with nivolumab in a patient with lung adenocarcinoma complicated by pulmonary aspergilloma
por: Furuya, Naoki, et al.
Publicado: (2020)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Fetal goiter identified in a pregnant woman with triiodothyronine-predominant graves’ disease: a case report
por: Fujishima, Akiko, et al.
Publicado: (2020)

Computed tomography imaging findings of nivolumab-induced thyroid dysfunction
por: Oki, Tatsuya, et al.
Publicado: (2022)

The role of all healthcare professionals in cessation
por: Devonish, Jazmin, et al.
Publicado: (2022)

The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer
por: Takegawa, Naoki, et al.
Publicado: (2023)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
por: Nakamura, Mikako, et al.
Publicado: (2023)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma
por: Yano, Seiichi, et al.
Publicado: (2018)

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m6hku7ua9df3q5iuib3h4hnfco